Valor202020212022202320242025TTMGastos comerciales, generales y administrativos6.93 B8.01 B8.99 B8.45 B8.6 B8.73 B8.73 BInvestigación y desarrollo1.18 B1.41 B1.47 B1.34 B1.39 B1.4 B1.4 BBeneficio operativo7.79 B10.03 B8.39 B6.86 B7.34 B7.75 B7.75 BTotal de ingresos no operativos18 M-560 M69 M701 M1.11 B864 M994 MGastos por intereses, netos de intereses capitalizados553 M536 M726 M1.38 B1.39 B1.42 B1.42 BIngresos no operativos, una vez deducidos los gastos por intereses-454 M-402 M-553 M-609 M-291 M-543 M-413 MIngresos/gastos extraordinarios-81 M-694 M-104 M-65 M12 M-12 M-12 MBeneficio antes de impuestos7.22 B8.84 B7.66 B6.24 B7 B7.27 B7.27 BParticipación en los beneficios—-4 M-172 M-59 M-42 M-41 M-41 MImpuestos850 M1.11 B703 M284 M657 M547 M547 MParticipación minoritaria—3 M10 M-40 M3 M17 M17 MOtros ingresos/gastos después de impuestos-340 M-190 M-524 M-604 M-508 M-455 M-455 MBeneficio neto antes de actividades interrumpidas6.38 B7.73 B6.96 B5.96 B6.34 B6.7 B6.7 BOperaciones suspendidas———————Beneficio neto6.38 B7.73 B6.96 B5.96 B6.34 B6.7 B6.7 BAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas6.38 B7.72 B6.95 B6 B6.33 B6.7 B6.7 BBeneficio básico por acción16.0919.6217.7515.5216.5817.7717.77Beneficio por acción diluido15.9619.4617.6315.4516.5317.7417.74Número medio de acciones ordinarias396 M394 M392 M386 M382 M377 M1.51 BAcciones diluidas399 M397 M394 M388 M383 M378 M1.51 BEBITDA10.12 B12.62 B11.77 B10.27 B10.45 B10.53 B13.11 BEBIT7.79 B10.03 B8.39 B6.86 B7.34 B7.75 B7.75 BCosto de los ingresos———————Otros costes de producción———————Amortización y depreciación (flujo de caja)2.33 B2.59 B3.38 B3.41 B3.11 B2.78 B5.36 B
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation, Alfa Aesar, Affymetrix, FEI Company, BD Advanced Bioprocessing, and PPD.
It ranked 104th on the Fortune 500 list based on its 2024 annual revenue of $42.879 billion.
Thermo Fisher announced a $2 billion investment over four years in the U.S., including $1.5 billion for expanding manufacturing capacity and $500 million for R&D investment. This initiative aims to bolster domestic biotech manufacturing, create high-paying jobs, and reinforce the U.S. healthcare supply chain.